Scarica l'app Stockscreener
26.26
1.43%
0.37
Pre-mercato:
26.38
0.12
+0.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$25.89
Aprire:
$26.2
Volume 24 ore:
3.28M
Relative Volume:
2.64
Capitalizzazione di mercato:
$3.21B
Reddito:
$588.99M
Utile/perdita netta:
$214.33M
Rapporto P/E:
15.59
EPS:
1.6844
Flusso di cassa netto:
$208.61M
1 W Prestazione:
+5.29%
1M Prestazione:
+12.56%
6M Prestazione:
+27.79%
1 anno Prestazione:
+16.61%
Intervallo 1D:
$25.85
$26.36
Intervallo di 1 settimana:
$24.69
$26.45
Portata 52W:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
26.26 | 3.21B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Catalyst Pharmaceuticals (CPRX) Is Up 5.3% After Stronger Revenue And Expanded M&A PipelineWhat's Changed - Sahm
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Institutional Support And Deal Pipeline Shape Outlook For Catalyst Pharmaceuticals - Yahoo Finance
Theravance Stock Declines Around 17% in Three Months: Here's Why - TradingView
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know - TradingView
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
See How Institutions Boost Catalyst Shares - Yahoo Finance Australia
Best Momentum Stock to Buy for March 4th - Eastern Progress
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Strength - Yahoo Finance
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup - ChartMill
Gains Recap: Is Catalyst Pharmaceuticals Incs growth already priced inMarket Trend Report & Verified Technical Signals - baoquankhu1.vn
Jim Cramer on Catalyst Pharmaceuticals: "It's a very inexpensive stock" - MSN
If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now - MSN
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView — Track All Markets
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock - ChartMill
Price Action: Will Catalyst Pharmaceuticals Inc benefit from government policy2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know - TradingView — Track All Markets
(CPRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Sahm
Bear Alert: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Extending Firdapse Exclusivity And Launching AgamreeHas The Bull Case Changed? - Yahoo Finance
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView — Track All Markets
Catalyst Pharmaceuticals, Inc. (CPRX) stock price, news, quote and history - Yahoo Finance UK
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is It Too Late To Consider Catalyst Pharmaceuticals (CPRX) After Strong Multi Year Rerating? - Sahm
Catalyst Pharmaceuticals, Inc. (CPRX) latest stock news and headlines - Yahoo Finance Australia
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - TradingView — Track All Markets
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Forecasts - Yahoo Finance
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - TradingView
Is Catalyst Pharmaceuticals (CPRX) Still Attractively Priced After Recent Share Price Stability? - Yahoo Finance
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
JPMorgan Chase & Co. Sells 54,915 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
New Strong Buy Stocks for March 31st - Yahoo Finance Singapore
Best Value Stocks to Buy for March 31st - Yahoo Finance Singapore
Aug Movers: Can Catalyst Pharmaceuticals Inc stock outperform in a bear marketEarnings Recap Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Trading And DCF Upside Signals - Yahoo Finance
Aug Mood: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Mixed Long Term And Recent Shareholder Returns - Sahm
Insider Buy: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Fundamental Recap & Long-Term Investment Growth Plans - baoquankhu1.vn
(CPRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Total Market Plus Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.19%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):